- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04000139
Anthocyanin Rich Extract (ACRE) in Patients With Ulcerative Colitis (ACRE)
A Multi-center, Multi-national, Randomized, Double-blind, Placebo Controlled, Parallel Group, Phase IIa Study to Evaluate the Efficacy, Safety and Tolerability of an Anthocyanin-rich Extract (ACRE) in Patients With Ulcerative Colitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
For anthocyanins (ACs), a wide range of protective biological effects have been described, such as anti-oxidative, anti-carcinogenic, anti-microbial and anti-inflammatory activities. Various research groups could identify a beneficial effect of ACs in IBD and intestinal inflammation.
A total of 112 subjects will be randomized. Subjects will be screened for eligibility between 0 and 28 days prior to baseline visit. At the baseline visit, subjects with moderate to severe ulcerative colitis (Mayo score ≥6) and fulfilling all inclusion/exclusion criteria will be randomized into two treatment arms (ACRE or placebo). Total duration of drug product administration will be 8 weeks (56 days) followed by a follow-up phase of 30 days.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland, 4031
- Universitätsspital Basel
-
Bern, Switzerland, 3010
- Inselspital Bern
-
Bern, Switzerland, 3012
- Gastroenterologische Praxis Balsiger, Seibold & Partner
-
Lausanne, Switzerland, 1011
- Centre Hospitalier Universitaire Vaudois
-
Saint Gallen, Switzerland, 9007
- Kantonsspital St. Gallen
-
Zürich, Switzerland, 8091
- Universitatsspital Zurich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female ≥ 18 years of age
- Established diagnosis of UC, with minimum time from diagnosis of ≥3 months
- Moderately at least left sided UC (disease should extend 15 cm or more above the anal verge). Disease severity determined by a Modified Mayo score of 6 to 12 with an endoscopic sub score ≥2 assessed by central reading of endoscopy performed at screening visit and no other individual sub score <1 (see 9.8.2 for more detailed information)
- Current oral or rectal 5-ASA/SP use or a history of oral or rectal 5-ASA/SP use
- Current steroids use or history of steroids dependency, refractory, or intolerance, including no steroids treatment due to earlier side-effects (only one of the steroids criteria have to be fulfilled, see definition in European Crohn´s and Colitis organization (ECCO) guidelines)
One of the following points must be fulfilled:
- Active disease despite induction therapy with 5-ASA agents where adequate therapy is considered with an oral 5-ASA (mesalamine 2- 4.8 g/day, sulfasalazine 4-6 g/day) administered for at least 2 weeks. Topical treatment with 5-ASA may have been attempted but this is not a prerequisite for inclusion in the study OR
- Intolerance to oral 5-ASAs or azathioprine OR
- Active disease despite a thiopurine (adequately dosed according to treatment guidelines, such as 2-3 mg/kg for azathioprine) or methotrexate administered for at least 12 weeks.
Allowed to receive a therapeutic dose of following UC drugs during the study:
- Oral steroids therapy (≤30 mg prednisone or equivalent/daily) providing that the dose has been stable for 2 weeks prior Baseline
- Oral or rectal MMX Budesonide therapy (9mg/daily) initiated and a stable dose at least 2 months before Baseline
- Oral or rectal 5-ASA/SP compounds, providing that the dose has been stable for 2 months prior to Baseline and initiated at least 8 weeks before screening.
- AZA/6-MP providing that the dose has been stable for 8 weeks prior to Baseline and been initiated at least 2 months before screening
- TNF inhibitors (Infliximab, Adalimumab or Golimumab) are allowed, providing that the dose is stable for at least 2 months prior to baseline and during the study treatment period
- Vedolizumab and Tofacitinib is allowed providing that the dose is stable for at least 2 months prior to baseline and during the study treatment period
- Ability to understand the treatment, willingness to comply with all study requirements and ability to provide informed consent
Exclusion Criteria:
Subjects fulfilling any of the following criteria are not eligible for inclusion in this study:
- Suspicion of differential diagnosis such as; Crohn's enterocolitis, ischaemic colitis, radiation colitis, indeterminate colitis, infectious colitis, diverticular disease, associated colitis, microscopic colitis, massive pseudopolyposis or non-passable stenosis
- Acute fulminant UC and/or signs of systemic toxicity
- UC limited to the rectum (disease which extends <15 cm above the anal verge)
History of malignancy, except for:
- Treated (cured) basal cell or squamous cell in situ carcinoma
- Treated (cured) cervical intraepithelial neoplasia or
- carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years prior to the screening visit
- History or presence of any clinically significant disorder that, in opinion of the investigator, could impact on patient's possibility to adhere to the protocol and protocol procedures or would confound the study result or compromise patient safety
- Long term treatment with antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs) within two weeks prior to screening (one short treatment regime for antibiotics and occasional use of NSAIDS are allowed)
- Serious active infection
- Gastrointestinal infections including positive Clostridium difficile stool assay
- Currently receiving parenteral nutrition or blood transfusions
- Females who are lactating or have a positive serum pregnancy test during the screening period
- Concurrent participation in another clinical study with investigational therapy or previous use of investigational therapy within 5 half-lives and within at least 30 days after last treatment of the experimental product prior to enrolment
Subjects who have been treated with
a. A dose of ≥ 1 mg per kg body weight prednisone or ≥30mg/d in the last 4 weeks prior to randomization.
- Ongoing treatment with cyclosporine or tacrolimus. Eligible subjects must have stopped cyclosporine and/or tacrolimus at least 4 weeks and antibiotics at least 1 week prior to randomization.
- known history of alcohol abuse, chronic liver or biliary disease
Repeated and confirmed laboratory findings showing:
- total bilirubin greater than 2 x upper limit of the normal range (ULN) unless in context of Gilbert's syndrome
- alkaline phosphatase (AP) greater than 2 x ULN
- ALT (SGPT) greater than 2 x ULN
- serum creatinine greater than 2 X ULN
- total white blood cell count (WBC) outside the range of 3,000 - 15,000 /μL. Subjects with mild leukocytosis (WBC not higher than 15,000 /μL) may be eligible, especially if the elevated WBC, according to the Investigator, is attributable to corticosteroid therapy and other causes such as hematological or infectious diseases can be excluded.
- platelet count <100,000/μL
- Hemoglobin less 8 g/dL and/or other signs of severe anemia.
- History or presence of a significant renal disease.
- Significant illness within the two weeks prior to dosing or any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study.
- Current history of active systemic bacterial, viral or fungal infections
- Presence or history of underlying metabolic, endocrine, hematologic, pulmonary, cardiac, blood, renal, hepatic, infectious, psychiatric or any medically unstable condition, as assessed by the primary treating physician which, in the opinion of the investigator, would place the subject at unacceptable risk for participation in the study.
- Known allergies to bilberries or any other AC containing fruits
- Planned diet change, any severe or new dietary restrictions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standardized anthocyanin rich extract
3 doses of 2x 500mg in capsules daily
|
3g of anthocyanin-rich extract taken daily as: 3 doses of 2x 500mg.
Treatment duration 56 days (8 weeks).
|
Placebo Comparator: Placebo
3 doses of 2x 500mg in capsules daily
|
3g of placebo taken daily as: 3 doses of 2x 500mg.
Treatment duration 56 days (8 weeks).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical response at week 8
Time Frame: 8 weeks
|
Proportion of patients with clinical response at week 8 where clinical response is defined as the reduction of total mayo score ≥ 3 points
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical remission at week 8
Time Frame: 8 weeks
|
Proportion of patients with symptomatic clinical remission at week 8, where clinical remission is defined as total mayo score ≤ 2, with no individual sub-score > 1
|
8 weeks
|
Rectal bleeding
Time Frame: 8 weeks
|
Proportion fo patients with absence of rectal bleeding at week 8, defined by the mayo subscore rectal bleeding of 0
|
8 weeks
|
Stool frequency
Time Frame: 8 weeks
|
Proportion of patients with normal or enhanced stool frequency at Week 8, defined by the Mayo sub score stool frequency of 0 or 1 (with at least one point decrease from Baseline, Week 0)
|
8 weeks
|
Endoscopic remission
Time Frame: 8 weeks
|
Proportion of patients with endoscopic remission at Week 8, defined by the Modified Mayo endoscopic sub score of 0 or 1 (excluding friability)
|
8 weeks
|
Histological remission
Time Frame: 8 weeks
|
Proportion of patients with histological remission at Week 8, defined by the Geboes Index of grade 0 or 1
|
8 weeks
|
Symptomatic remission
Time Frame: 4 weeks
|
Proportion of patients with symptomatic remission at Week 4, defined by the Mayo sub scores, i) rectal bleeding of 0, ii) stool frequency of 0 or 1 (with at least one point decrease from Baseline, Week 0), (patient reported outcome)
|
4 weeks
|
Rectal bleeding week 4
Time Frame: 4 weeks
|
Proportion of patients with absence of rectal bleeding at Week 4, defined by the Mayo sub score rectal bleeding of 0
|
4 weeks
|
Stool frequency week 4
Time Frame: 4 weeks
|
Proportion of patients with normal or enhanced stool frequency at Week 4, defined by the Mayo sub score stool frequency of 0 or 1 (with at least one point decrease from Baseline, Week 0)
|
4 weeks
|
Durable symptomatic remission
Time Frame: 8 weeks / 12 weeks
|
Proportion of patients with durable symptomatic remission, defined by the Mayo sub scores, i) rectal bleeding of 0, ii) stool frequency of 0 or 1 (with at least one point decrease from Baseline, Week 0) [PRO2] at both Week 8 and Week 12
|
8 weeks / 12 weeks
|
Clinical response
Time Frame: 8 weeks
|
Proportion of patients with clinical response at Week 8, defined as clinical remission or a three point and ≥30 % decrease from Baseline, Week 0 in the sum of the Modified Mayo score, i) rectal bleeding, ii) stool frequency and iii) endoscopy score (excluding friability), iiii) physicians global assessment (PGA)
|
8 weeks
|
Fecal calprotectin
Time Frame: 8 weeks
|
Mean change in fecal calprotectin at Week 1, 2, 4, and 8 compared to Baseline, Week 0.
|
8 weeks
|
Steroid dosage
Time Frame: 4 weeks (follow-up phase)
|
Mean change in steroid dosage for patients in remission at Week 8 to Week 12
|
4 weeks (follow-up phase)
|
SIBDQ
Time Frame: 8 weeks
|
Mean change in each of the short inflammatory bowel disease questionnaire (SIBDQ) sub domains at Week 8 compared to Baseline, Week 0 SIBDQ data will consist of 10 individual items, scores for the 4 dimensions (bowel function, emotional status, systemic symptoms and social function) and a total score.
All data will be listed and data for the 4 dimensions and total score summarized by time post-dose for each dose.
Week 8 changes from baseline for the 4 dimensions and total score will be plotted and summarized by dose to visually assess dose-related changes.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Gerhard Rogler, Prof. Dr. med. Dr. phil., Universitatsspital Zurich
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACRE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...CompletedIntensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET (In-TARGET)ULCERATIVE COLITISFrance, Belgium
-
Xijing Hospital of Digestive DiseasesNot yet recruitingUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Severe | Rectal UlcerChina
Clinical Trials on Standardized anthocyanin-rich extract
-
Neuromed IRCCSCompletedToxicity Due to RadiotherapyItaly
-
Antigen Laboratories, Inc.Completed
-
Shahid Beheshti UniversityShahid Beheshti University of Medical SciencesRecruiting
-
Neuromed IRCCSTerminatedCoronary Heart DiseaseItaly
-
9305-9954 Quebec IncMcMaster UniversityWithdrawnChronic Pain | InsomniaCanada
-
Greer LaboratoriesCompletedAllergic RhinitisUnited States
-
Neurophenols ConsortiumLaval University; Atrium Innovations; Activ'inside; Fruit d'Or; Laboratoire NutriNeuro... and other collaboratorsCompletedHealthy ElderlyFrance, Canada
-
Milsing d.o.o.CompletedMild Cognitive Impairment | Cerebrovascular InsufficiencyCroatia
-
Medika Natura Sdn BhdZach Biotech Depot Sdn BhdCompleted
-
Antigen Laboratories, Inc.WithdrawnAllergic Rhinitis